Paspala Anna, Machairas Nikolaos, Prodromidou Anastasia, Spartalis Eleftherios, Ioannidis Argyrios, Kostakis Ioannis D, Papaconstantinou Dimetrios, Nikiteas Nikolaos
Laboratory of Experimental Surgery and Surgical Research, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece.
Second Department of General Surgery, 'Sismanoglio' General Hospital, 15126 Athens, Greece.
Mol Clin Oncol. 2018 Aug;9(2):219-222. doi: 10.3892/mco.2018.1649. Epub 2018 Jun 11.
Mixed adeno-neuroendocrine carcinoma (MANEC) is a rare pathological diagnosis recently acknowledged by the World Health Organization in 2010. MANEC is a neoplasm characterized by significant histological heterogeneity and is characterized by the simultaneous presence of both adenocarcinomatous and neuroendocrine differentiation; their definition includes each component found in at least 30% of the tumor. Colorectal MANEC constitutes an uncommon type of malignant tumor. The true prevalence of colorectal MANEC has not been precisely defined and published studies are limited to case reports and small case series. The aim of the present review was to accumulate the existing evidence on colorectal MANEC with special attention to the clinicopathological characteristics, management and survival rates of patients diagnosed with this malignancy. A total of 20 studies (16 case reports and 4 retrospective cohorts) reported outcomes for patients with colorectal MANEC and were finally considered eligible for analysis. The results of the present study show that patients with early stage MANEC have more favorable survival compared to those diagnosed in advanced stages. Due to its neuroendocrine nature, which is characterized by rapid progression, MANEC is diagnosed in advanced stages in the majority of cases and thus potentially explains the poor survival rates. Because of its aggressive nature and high recurrence rate, adjuvant chemotherapy constitutes a critical part of the treatment and significantly improves survival. Further larger studies are needed in order to establish guidelines for the treatment of these rare lesions.
混合性腺神经内分泌癌(MANEC)是世界卫生组织于2010年新认可的一种罕见病理诊断。MANEC是一种具有显著组织学异质性的肿瘤,其特征是同时存在腺癌和神经内分泌分化;其定义包括肿瘤中至少30%出现的每种成分。结直肠MANEC是一种少见的恶性肿瘤类型。结直肠MANEC的真实患病率尚未精确界定,已发表的研究仅限于病例报告和小病例系列。本综述的目的是积累关于结直肠MANEC的现有证据,特别关注诊断为此种恶性肿瘤的患者的临床病理特征、治疗方法和生存率。共有20项研究(16篇病例报告和4个回顾性队列研究)报告了结直肠MANEC患者的治疗结果,最终被认为符合分析条件。本研究结果表明,早期MANEC患者的生存率比晚期诊断的患者更有利。由于其神经内分泌性质,其特点是进展迅速,大多数病例在晚期才被诊断出来,这可能解释了生存率较低的原因。由于其侵袭性和高复发率,辅助化疗是治疗的关键部分,可显著提高生存率。需要进一步开展更大规模的研究,以便为这些罕见病变的治疗制定指南。